Valeant snaps up Salix Pharma in $14.5 billion deal
As had been widely rumoured, Valeant Pharmaceuticals International is buying Salix Pharmaceuticals in a deal valued at $14.5 billion.
Read MoreAuthor: Kevin Grogan
Novo’s oral version of semaglutide impresses in Phase II
Shares in Novo Nordisk have risen after the Danish company presented positive mid-stage results on OG217SC, an oral formulation of its long-acting GLP-1 analogue semaglutide.
Read MoreIT overtakes pharma for UK R&D activity
The UK software industry now has more professionals engaged in innovative activity than any other sector of the economy and “has eclipsed the once-dominant pharmaceuticals industry”.
Read MorePfizer seeks Rapamune approval for rare lung disease
Pfizer says the US Food and Drug Administration has accepted for priority review a supplemental New Drug Application of its immunosuppressant Rapamune for lymphangioleiomyomatosis, a rare, often-fatal lung disease.
Read MoreNICE backs Bayer’s Eylea after discount deal
The National Institute for Health and Care Excellence has recommended Bayer’s Eylea as an option for diabetic macular oedema in preliminary recommendations, having agreed a discount with the company.
Read More- Kahimmune Therapeutics enters licensing agreement with Gustave Roussy and SATT Paris-Saclay
- IBSA UK&I launches Perovial for the treatment of acute Peyronie’s disease
- En Carta Diagnostics’ EC Pocket Lyme test receives FDA Breakthrough Device Designation
- ALK’s EURneffy receives positive CHMP opinion for emergency anaphylaxis treatment in children
- CERo reports encouraging early data from phase 1 trial of CER‑1236
